



RECEIVED
FEB 2 2002
TECH CENTER 1600/2900
161

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,151,273	04-24-1979	Riegelman et al.	424/78
4,332,721	06-01-1982	Bernini et al.	260/239.57
4,384,975	05-24-1989	Fong et al.	427/213.36
4,757,128	07-12-1988	Domb et al.	528/271
4,997,904	03-05-1991	Domb	528/206
5,043,280	08-27-1991	Fischer et al.	435/235.1
5,175,235	12-29-1992	Domb et al.	528/271

5,354,562	10-11-1994	Platz et al.	424/489
5,407,609	04-18-1995	Tice, et al.	264/46
5,639,441	06-17-1997	Sievers et al.	424/9.3
5,667,808	09-16-1997	Johnson et al.	424/501
5,700,471	12-23-1997	End et al.	424/400
5,747,002	05-05-1998	Clark et al.	424/45
5,776,495	07-07-1998	Duclos et al.	424/455
5,780,062	07-14-1998	Frank et al.	424/501
5,800,834	09-01-1998	Spireas et al	424/451
5,817,343	10-06-1998	Burke	424/489
5,833,891	11-10-1998	Subramaniam et al.	264/7
5,851,453	12-22-1998	Hanna et al.	264/5
5,855,913	01-05-1999	Hanes et al.	424/489
5,874,029	02-23-1999	Subramaniam et al.	264/12
5,874,064	02-23-1999	Edwards et al.	424/46
5,952,008	09-14-1999	Backstrom et al.	424/499

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 97/35563 A	10-02-1997	Takeda Chemical Industries	PCT
WO 97/03702 A	02-06-1997	Brown University Research Foundation	PCT
WO 97/03657 A	02-06-1997	Brown University Research Foundation	PCT
WO 98/46212 A	10-22-1998	Amgen Inc.	PCT
0 225 162 A	06-10-1987	Ethicon, Inc.	EP

Publications

KORNBLUM, "Sustained-action tablets prepared by employing a spray-drying technique for granulation," *J Pharm Sci* 58(1):125-27 (1969).

SAWHNEY, et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(a-hydroxy acid) Diacrylate Macromers," *Macromolecules* 26:581-587 (1993).

TRACY, "Development and scale-up of a microsphere protein delivery system," *Biotechnol. Prog* 14:108-15 (1998).

WEHRLE, et al., "The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design," *European Journal of Pharmaceutics and Biopharmaceutics* 41(1):19-26 (1995).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: February 7, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8500
FAX 404-817-0470
www.hklaw.com

U.S.S.N.: 09/760,046
Filed: January 12, 2001
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: February 7, 2002


Kimberly L. Adams